Epidiolex® sales continue to rise.
Third party news and news dissemination provider Market New Updates recently released a report containing the newest advancements and breakthroughs for patents and therapies. The specific therapies they included are those that target diseases including (but not limited to) cancer and other rare conditions. This week’s report contains new developments from Puration, Inc. (OTC: PURA), GW Pharmaceuticals plc (NASDAQ: GWPH), CV Sciences Inc. (OTC: CVSI), 22nd century Group Inc. (NASDAQ: XXII) and PotNetwork Holding Inc. (OTC: POTN).
For the purpose of being concise in this post, we want to focus on the freshest news from leading corporation in cannabinoid medicines GW Pharmaceuticals. When it comes to GW Pharmaceuticals plc., they closed up huge last week with over 300,000 market shares. These results are due to the newest product from the company. The New England Journal of Medicine publishing results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome has also boosted sales for GW Pharma. Afterall, Epidiolex® could be the first ever product of its kind in the category of antiepileptic drugs.
Epidiolex® is the second product released for public consumption by GW Pharmaceuticals, a company dedicated to developing plant-derived cannabinoid therapeutics. Their first product, Sativex® has been involved in mulitple studies includign one to prove the efficacy of THC in treating the symptoms of ADHD.
GW’s vision is to be the global leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which address clear unmet needs.
-Justin Gover, Chief Executive Officer
Epidiolex® is a purified, liquid plant derived extraction of cannabidiol (CBD), the more prominently known non-psychoactive chemical compound naturally occurring in cannabis. Currently, CBD is being studied for a number of rare and severe pediatric-onset epileptic disorders. The study we mentioned above that was published in the New England Journal of Medicine noted that Epidiolex® significantly reduced the frequency of convulsive seizures in highly treatment-resistant children when added to existing treatment. In all cases, Epidiolex® was well tolerated by participants.